Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2526)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5696)
  2. Department of Medicine (5686)
  3. GSK Faculty (1659)
  4. Human Oncology and Pathogenesis Program (1158)
  5. Department of Pathology and Laboratory Medicine (1130)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (786)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (204)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (690)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5696)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pilot investigation of variants in DNA repair pathways and association with response to platinum-based chemotherapy in bladder cancer
    Meeting Abstract

    Kopp, R. P.; Stratton, K. L.; Garcia-Grossman, I. R.; Zabor, E. C.; Ostrovnaya, I.; Thomas, T.; Gerber, G.; Alanee, S. R.; Schrader, K. A.; O'Donnell, P. H.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Using exon-capture, deep sequencing of high-grade bladder urothelial carcinoma to identify recurrent genetic alterations and potential therapeutic targets
    Meeting Abstract

    Kim, P. H.; Sfakianos, J. P.; Scott, S. N.; Iyer, G.; Cha, E. K.; Al-Ahmadie, H.; Sun, A. J.; Garcia-Grossman, I. R.; Bambury, R. M.; Dalbagni, G.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Development and validation of a prognostic nomogram for progression-free and overall survival in patients with advanced renal cell carcinoma (aRCC) treated with pazopanib
    Meeting Abstract

    Kattan, M. W.; Sternberg, C. N.; Mehmud, F.; Bhatt, K.; Chakrabarti, D.; McCann, L.; Motzer, R. J.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma
    Meeting Abstract

    Hakimi, A. A.; Ostrovnaya, I.; Jacobsen, A.; Coleman, J. A.; Russo, P.; Mano, R.; Sankin, A.; Motzer, R. J.; Purdue, M.; Pomerantz, M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Integrated analysis of metastatic disease in clear cell renal cell carcinoma: A collaborative TCGA analysis
    Meeting Abstract

    Hakimi, A. A.; Jacobsen, A.; Mano, R.; Gonen, M.; Voss, M. H.; Reuter, V. E.; Rathmell, K.; Maranchie, J. K.; Appleman, L. J.; Tamboli, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Mitogen-activated protein kinase (MAPK) pathway mutations impact phenotype and survival in colorectal liver metastases
    Meeting Abstract

    Frankel, T. L.; Vakiani, E.; DeMatteo, R.; Allen, P.; Fong, Y.; Kingham, T.; Jarnagin, W.; Solit, D.; D'Angelica, M.
    Annals of Surgical Oncology (2014)

    Fulltext@MSK | Save
  • Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials
    Meeting Abstract

    Fizazi, K.; Flaig, T. W.; Ohlmann, C. H.; Scher, H. I.; de Bono, J. S.; Rathkopf, D. E.; Ryan, C. J.; Kheoh, T. S.; Li, J. H.; Todd, M. B.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Evaluating 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) and FDG PET as prognostic biomarkers for patients (pts) treated with abiraterone acetate (AA)
    Meeting Abstract

    Feldman, J. L.; Fox, J. J.; Autio, K. A.; Gavane, S. C.; Heller, G.; Schoder, H.; Humm, J.; Martinez, D. F.; Slovin, S. F.; Scher, H. I.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Multicenter sequential phase II study of flavopiridol plus oxaliplatin (Alvocidib) with or without 5-FU and leucovorin (LV) for patients (pts) with refractory germ cell tumors (GCT) including late relapse (LR)
    Meeting Abstract

    Feldman, D. R.; Stadler, W. M.; Appleman, L. J.; Quinn, D. I.; Costello, B. A.; Schwartz, G. K.; Reuter, V. E.; Woo, K.; Patil, S.; Fusco, A.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway-targeted therapy and one prior mTOR inhibitor therapy
    Meeting Abstract

    Escudier, B. J.; Porta, C.; Squires, M.; Szczylik, C.; Kollmannsberger, C. K.; Melichar, B.; Rha, S. Y.; Esteban, E.; Bjarnason, G. A.; Vogelzang, N. J.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save